Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2020 | 1 |
2021 | 2 |
2022 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol. 2022 Jul;23(7):851-864. doi: 10.1016/S1470-2045(22)00284-4. Epub 2022 Jun 4.
Lancet Oncol. 2022.
PMID: 35671774
Free PMC article.
Clinical Trial.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ.
Jones RH, et al. Among authors: bezecny p.
Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5.
Lancet Oncol. 2020.
PMID: 32035020
Free PMC article.
Clinical Trial.
Item in Clipboard
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P.
Bezecny P.
Med Oncol. 2014 Jun;31(6):985. doi: 10.1007/s12032-014-0985-5. Epub 2014 May 18.
Med Oncol. 2014.
PMID: 24838514
Review.
Item in Clipboard
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Bahl A, Wilson W, Ball J, Renninson E, Dubey S, Bravo A, Foulstone E, Spensley S, Bowen R, Mansi J, Waters S, Riddle P, Wheatley D, Stephens P, Bezecny P, Madhusudan S, Verrill M, Braybrooke J, Comins C, Mohan V, Gee A, Kirk H, Markham A, Evans H, Watson E, Callaway M, Pearson S, Hackshaw A, Churn M.
Bahl A, et al. Among authors: bezecny p.
Breast. 2022 Dec;66:69-76. doi: 10.1016/j.breast.2022.09.005. Epub 2022 Sep 24.
Breast. 2022.
PMID: 36194950
Free PMC article.
Clinical Trial.
Item in Clipboard
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study.
El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M, Desouza K, Dixon S, Hills D, Moe M, Pigott T, Proctor A, Shah Y, Simcock R, Stansfeld A, Synowiec A, Theodoulou M, Verrill M, Wadhawan A, Harper-Wynne C, Wilson C.
El Badri S, et al. Among authors: bezecny p.
Breast. 2021 Dec;60:199-205. doi: 10.1016/j.breast.2021.10.010. Epub 2021 Oct 28.
Breast. 2021.
PMID: 34736090
Free PMC article.
Item in Clipboard
Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer.
Alhebshi H, Tian K, Patnaik L, Taylor R, Bezecny P, Hall C, Muller PAJ, Safari N, Creamer DPM, Demonacos C, Mutti L, Bittar MN, Krstic-Demonacos M.
Alhebshi H, et al. Among authors: bezecny p.
Int J Mol Sci. 2021 Dec 7;22(24):13198. doi: 10.3390/ijms222413198.
Int J Mol Sci. 2021.
PMID: 34947995
Free PMC article.
Item in Clipboard
Cite
Cite